Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics natural incretin hormones to regulate blood glucose and promote weight loss. Available as FDA-approved Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as the first oral GLP-1 medication. Clinical trials demonstrate exceptional efficacy with 14.9% average weight loss and 26% reduction in major cardiovascular events.
Complete Research Database
Clinical Efficacy by Dose
Medical Disclaimer
Semaglutide is FDA-approved as Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as oral GLP-1 therapy. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.